Agile Therapeutics Q1 2024 Adj EPS $(0.63) Misses $(0.51) Estimate, Sales $5.72M Beat $3.75M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics (NASDAQ:AGRX) reported Q1 2024 adjusted EPS of $(0.63), missing the $(0.51) estimate, but achieved sales of $5.72M, beating the $3.75M estimate. Sales increased by 49.91% compared to the same period last year.
May 15, 2024 | 8:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Agile Therapeutics reported a Q1 2024 EPS miss but a significant sales beat. The EPS of $(0.63) missed the $(0.51) estimate by 23.53%, while sales of $5.72M beat the $3.75M estimate by 52.35%, showing a 49.91% YoY increase.
The mixed results, with an EPS miss but a strong sales beat, create a neutral short-term impact. Investors may weigh the negative EPS against the positive sales growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100